Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Net Cash Flow (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Net Cash Flow for 14 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 424.12% year-over-year to $6.0 million, compared with a TTM value of $10.6 million through Dec 2025, up 198.22%, and an annual FY2025 reading of $10.6 million, up 198.22% over the prior year.
  • Net Cash Flow was $6.0 million for Q4 2025 at Fate Therapeutics, up from -$627000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $79.5 million in Q1 2024 and bottomed at -$84.4 million in Q2 2024.
  • Average Net Cash Flow over 5 years is -$6.3 million, with a median of -$2.8 million recorded in 2024.
  • The sharpest move saw Net Cash Flow tumbled 4108.15% in 2021, then skyrocketed 511.39% in 2024.
  • Year by year, Net Cash Flow stood at $4.4 million in 2021, then tumbled by 571.5% to -$20.8 million in 2022, then soared by 141.12% to $8.5 million in 2023, then tumbled by 121.71% to -$1.9 million in 2024, then soared by 424.12% to $6.0 million in 2025.
  • Business Quant data shows Net Cash Flow for FATE at $6.0 million in Q4 2025, -$627000.0 in Q3 2025, and -$3.7 million in Q2 2025.